Intensity Therapeutics Inc
NASDAQ:INTS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Intensity Therapeutics Inc
Total Equity
Intensity Therapeutics Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
Intensity Therapeutics Inc
NASDAQ:INTS
|
Total Equity
$2.9m
|
CAGR 3-Years
30%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Equity
-$2.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Equity
$21.5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Equity
$9.6B
|
CAGR 3-Years
38%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-10%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Equity
$17.3B
|
CAGR 3-Years
10%
|
CAGR 5-Years
16%
|
CAGR 10-Years
34%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Equity
$31.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
23%
|
CAGR 10-Years
24%
|
|
Intensity Therapeutics Inc
Glance View
Intensity Therapeutics, Inc. engages in the operation a biotechnology company which develops novel immune-based therapeutic products for cancer treatment. The company is headquartered in Westport, Connecticut and currently employs 3 full-time employees. The company went IPO on 2023-06-30. The firm is engaged in developing an approach to treat solid tumor cancers. The company leverages its DfuseRx technology platform to create proprietary drug formulations. Its product candidates have the potential to induce an adaptive immune response that attacks the injected and non-injected tumors. The firm's lead product candidate, INT230-6, is in development for the treatment of patients with solid tumors, such as sarcoma and breast cancer patients. The Company, through Merck Sharpe & Dohme (Merck), evaluates INT230-6 with pembrolizumab. In addition, it also evaluates the combination INT230-6 with Bristol-Myers Squibb's anti-CTLA-4 antibody, ipilimumab. The company also has an agreement with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer (the INVINCIBLE study) (NCT04781725).
See Also
What is Intensity Therapeutics Inc's Total Equity?
Total Equity
2.9m
USD
Based on the financial report for Dec 31, 2024, Intensity Therapeutics Inc's Total Equity amounts to 2.9m USD.
What is Intensity Therapeutics Inc's Total Equity growth rate?
Total Equity CAGR 3Y
30%
Over the last year, the Total Equity growth was -78%. The average annual Total Equity growth rates for Intensity Therapeutics Inc have been 30% over the past three years .
